VMSDC
0.155
203.9%
1TT
0.002
-33.3%
SFG
0.003
50%
ERA
0.002
-33.3%
ATS
0.018
38.5%
LIB
0.002
-33.3%
G88
0.008
33.3%
LNU
0.002
-33.3%
LAT
0.072
30.9%
RDS
0.002
-33.3%
AVE
0.009
28.6%
BOA
0.026
-23.5%
SRL
6.17
26.2%
EZZ
1.86
-19.5%
CLE
0.058
26.1%
PRO
0.15
-18.9%
BYH
0.005
25%
IPT
0.005
-16.7%
ENT
0.005
25%
PLC
0.005
-16.7%
NHE
0.045
25%
L1M
0.032
-15.8%
LMS
0.63
23.5%
CPO
0.011
-15.4%
CBE
0.135
22.7%
TDO
0.165
-15.4%
DGR
0.022
22.2%
SOP
0.023
-14.8%
KGL
0.17
21.4%
AX8
0.006
-14.3%
IBX
0.023
21.1%
LCL
0.006
-14.3%
4DS
0.012
20%
RGL
0.006
-14.3%
CAV
0.006
20%
MRD
0.034
-12.8%
HPC
0.006
20%
NZK
0.17
-12.8%
RCR
0.018
20%
FIN
0.007
-12.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747